Savara (SVRA)
(Real Time Quote from BATS)
$4.75 USD
+0.07 (1.50%)
Updated May 3, 2024 11:38 AM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
SVRA 4.75 +0.07(1.50%)
Will SVRA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SVRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SVRA
Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks
3 Top Breakout Stocks to Add to Your Portfolio Now
SVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
Other News for SVRA
Optimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial Success
Savara management to meet with Oppenheimer
JMP Securities biotech analysts to hold an analyst/industry conference call
JMP Securities biotech analysts to hold an analyst/industry conference call
Savara management to meet with Oppenheimer